A self-designed and developed 12/10 switched reluctance motor(SRM)is chosen as the object of study and a prototype of 2.5?kW switched reluctance starter/generator with fly-wheel is designed based on the requirements o...A self-designed and developed 12/10 switched reluctance motor(SRM)is chosen as the object of study and a prototype of 2.5?kW switched reluctance starter/generator with fly-wheel is designed based on the requirements of the selected engine (Changan Aotooc three-cylinder engine wagon) for the starter, generator and drive. The 36?V/42 V DC source system is applied to establishing the simulation-analyzing model of the motor. A finite-element (FE) analysis of its two-dimensional electromagnetic field is conducted to obtain the exact model of the motor. Systematic simulation is carried out combining with its power conversion circuit and control element. Meanwhile the starting process and performance of the system are studied and analyzed with special efforts. Satisfactory result is derived from the testing of the prototype: theoretical analysis is basically matched with the tested data, which proves the rationality and feasibility of the design procedures, systematic modeling and control strategies. Therefore, the new 12/10-structure scheme is put forward based on the development and analysis of various SRM and it meets the requirements of the researched motor in terms of the structural parameters.展开更多
Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acut...Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acute demyelination shows as clinical relapses that may fully or partially resolve, while chronic demyelination and neuroaxonal injury lead to persistent and irreversible neurological symptoms, often progressing over time. Currently approved disease-modifying therapies are immunomodulatory or immunosuppressive drugs that significantly although variably reduce the frequency of attacks of the relapsing forms of the disease. However, they have limited efficacy in preventing the transition to the progressive phase of MS and are of no benefit after it has started. It is therefore likely that the potential advantage of a given treatment is condensed in a relatively limited window of opportunity for each patient, depending on individual characteristics and disease stage, most frequently but not necessarily in the early phase of the disease. In addition, a sizable proportion of patients with MS may have a very mild clinical course not requiring a disease-modifying therapy. Finally, individual response to existing therapies for MS varies significantly across subjects and the risk of serious adverse events remains an issue, particularly for the newest agents. The present review is aimed at critically describing current treatment strategies for MS with a particular focus on the decision of starting, switching and stopping commercially available immunomodulatory and immunosuppressive therapies.展开更多
文摘A self-designed and developed 12/10 switched reluctance motor(SRM)is chosen as the object of study and a prototype of 2.5?kW switched reluctance starter/generator with fly-wheel is designed based on the requirements of the selected engine (Changan Aotooc three-cylinder engine wagon) for the starter, generator and drive. The 36?V/42 V DC source system is applied to establishing the simulation-analyzing model of the motor. A finite-element (FE) analysis of its two-dimensional electromagnetic field is conducted to obtain the exact model of the motor. Systematic simulation is carried out combining with its power conversion circuit and control element. Meanwhile the starting process and performance of the system are studied and analyzed with special efforts. Satisfactory result is derived from the testing of the prototype: theoretical analysis is basically matched with the tested data, which proves the rationality and feasibility of the design procedures, systematic modeling and control strategies. Therefore, the new 12/10-structure scheme is put forward based on the development and analysis of various SRM and it meets the requirements of the researched motor in terms of the structural parameters.
文摘Multiple sclerosis(MS) is a chronic inflammatory condition of the central nervous system determined by a presumed autoimmune process mainly directed against myelin components but also involving axons and neurons. Acute demyelination shows as clinical relapses that may fully or partially resolve, while chronic demyelination and neuroaxonal injury lead to persistent and irreversible neurological symptoms, often progressing over time. Currently approved disease-modifying therapies are immunomodulatory or immunosuppressive drugs that significantly although variably reduce the frequency of attacks of the relapsing forms of the disease. However, they have limited efficacy in preventing the transition to the progressive phase of MS and are of no benefit after it has started. It is therefore likely that the potential advantage of a given treatment is condensed in a relatively limited window of opportunity for each patient, depending on individual characteristics and disease stage, most frequently but not necessarily in the early phase of the disease. In addition, a sizable proportion of patients with MS may have a very mild clinical course not requiring a disease-modifying therapy. Finally, individual response to existing therapies for MS varies significantly across subjects and the risk of serious adverse events remains an issue, particularly for the newest agents. The present review is aimed at critically describing current treatment strategies for MS with a particular focus on the decision of starting, switching and stopping commercially available immunomodulatory and immunosuppressive therapies.
